## DISSERTATION

ON

# DEFEROXAMINE LOADED TOPICAL THERMO SENSITIVE GEL FOR TREATMENT OF DIABETIC FOOT ULCER

Submitted for the partial fulfillment of the requirement for

The Award of Degree of MASTER OF PHARMACY (PHARMACEUTICS)

Session 2020-2022



Supervisor Dr. K. P. MEENA (M. Pharm., Ph.D.) ASSISTANT PROFESSOR [PHARMACEUTICS]

Submitted by TRIPTY KARRI M. Pharm IV Semester [PHARMACEUTICS] Enroll No: GGV/16/6190 Roll No: 20704008

DEPARTMENT OF PHARMACY, GURU GHASIDAS VISHWAVIDYALAYA, A CENTRAL UNIVERSITY, BILASPUR (C.G.) 495009

Abid Printer - 9770398993

## A DISSERTATION ON

# DEFEROXAMINE-LOADED TOPICAL THERMOSENSITIVE GEL FOR TREATMENT OF DIABETIC FOOT ULCER

Submitted for the partial fulfillment of the requirement for

The Award of Degree of MASTER OF PHARMACY (PHARMACEUTICS) Session 2020-2022



Supervisor Dr. K. P. MEENA (M. Pharm., Ph.D.)

ASSISTANT PROFESSOR [PHARMACEUTICS] Submitted by TRIPTY KARRI M. Pharm IV Semester [PHARMACEUTICS] Enroll No: GGV/16/6190 Roll No: 20704008

## DEPARTMENT OF PHARMACY, GURU GHASIDAS VISHWAVIDYALAYA, A CENTRAL UNIVERSITY, BILASPUR (C.G.) 495009



DEPARTMENT OF PHARMACY, GURU GHASIDAS VISHWAVIDYALAYA, BILASPUR 495009 (C.G.) (A Central University Established by the Central University Act-2009 No-25 of 2009) Tel.No.07752-260027; FaxNo.07752-260148.

#### FORWARDING CERTIFICATE

This is to certify that Miss TRIPTY KARRI M. Pharm IV semester (Pharmaceutics) of this institute has submitted her dissertation work entitled "DEFEROXAMINE-LOADED TOPICAL THERMOSENSITIVE GEL FOR TREATMENT OF DIABETIC FOOT ULCER" for the partial fulfillment of the requirement for the award of degree of Master of Pharmacy (Pharmaceutics) with her truly and honestly observed inference during his research work under the supervision of Dr. K. P. MEENA. Her work is original, satisfactory and is not submitted anywhere else for the award of any degree.

I hereby forward her thesis for the award of M. Pharm degree in Pharmaceutics during the academic session 2020-2022.

ror HEAD OF DEPARTMEN

Head of Department, Department of pharmacy, Guru Ghasidas Vishwavidyalaya, A Central University, Bilaspur (C.G.)

Head

Department of Pharmacy Guru Ghasidas Vishwavidyalaya (A Central University) Bilaspur (C.G.) Date



DEPARTMENT OF PHARMACY, GURU GHASIDAS VISHWAVIDYALAYA, BILASPUR 495009 (C.G.) (A Central University Established by the Central University Act-2009 No-25 of 2009) Tel.No.07752-260027; FaxNo.07752-260148.

#### **CERTIFICATE**

This is to certify that Miss TRIPTY KARRI D/O Mr. KAMLESH KUMAR KARRI, M. Pharm final Semester (Pharmaceutics) of department of pharmacy, has submitted his dissertation work entitled "DEFEROXAMINE-LOADED TOPICAL THERMOSENSITIVE GEL FOR TREATMENT OF DIABETIC FOOT ULCER" for the partial fulfillment of the requirement for the Award of Degree of Master of Pharmacy (Pharmaceutics) with her truly & honestly observed inference during her research work. She has completed her project work under my guidance. Her work is original, satisfactory and is not submitted anywhere else for any degree.

I hereby forward his synopsis for the award of Master of Pharmacy (Pharmaceutics) during the academic session 2020-2022.

146' Dr. K. P. MEENA

M. Pharm., Ph.D.

Assistant Professor (Pharmaceutics) (Supervised Prasad Meena M. Pharm., Ph.D. Assistant Professor (Pharmaceutics) (151. of Pharm. Sciences) (151. of Pharm. Sciences) (151. of Pharm. Sciences)



DEPARTMENT OF PHARMACY, GURU GHASIDAS VISHWAVIDYALAYA, BILASPUR 495009 (C.G.) (A Central University Established by the Central University Act-2009 No-25 of 2009) Tel.No.07752-260027; FaxNo.07752-260148.

#### **DECLARATION**

I hereby declare that my M. Pharm synopsis work entitled "DEFEROXAMINE-LOADED TOPICAL THERMOSENSITIVE GEL FOR TREATMENT OF DIABETIC FOOT ULCER" is my own work conducted under the supervision of Dr. K. P. MEENA. The same is submitted to the SLT Institute of Pharmaceutical Sciences, Guru Ghasidas Vishwavidyalaya, Bilaspur (C.G.) for the partial fulfillment of the requirement for the Award of Degree of Master of Pharmacy in Pharmaceutics during the academic session 2021-2022.

I further declare that to the best of my knowledge the thesis does not contain any part of work, which has been submitted for the award of any degree either in the University or in any other University/ Deemed University without proper citation.

Date: 31 10 22

Place: Bilaspur

TRIPTY KARRI

M. Pharm Final Semester

### ACKNOWLEDGEMENT

First and foremost, praises and thanks to the God, the Almighty, for his showers of blessing throughout my research work to complete the research successfully.

I would like to express my deep and sincere gratitude to my research supervisor, **Dr. K. P. MEENA**, M. Pharm., Assistant Professor, Department of Pharmacy, Guru Ghasidas Vishwavidyalaya, A Central university, Bilaspur (C.G.), for giving me the opportunity to do research and providing invaluable guidance throughout this research. His dynamism, vision, sincerity and motivation have deeply inspired me. He has taught me the methodology to carry out the research and to present the research works as clearly as possible. It was a great privilege and honor to work and study under his guidance. I am extremely grateful for what he has offered me. I would also like to thank him for his friendship, empathy, and great sense of humor. I am extending my heartfelt thanks for his acceptance and patience during the discussion I had with on research work and thesis preparation.

I take pride in acknowledging the insightful guidance of **Dr. Bharti Ahirwar** Professor and Head of Department, Department of pharmacy, Guru Ghasidas Vishwavidyalaya, A Central University, Bilaspur (C.G.), for sparing his valuable time whenever I approached him and showing me the way ahead despite of his busy schedule.

I would like to offer my special thanks to **Dr. Ravi Shankar Pandey**, M. Pharm., PhD., Assistant Professor, Department of Pharmacy Guru Ghasidas Vishwavidyalaya, Bilaspur (C.G.) without his enthusiasm, encouragement, support and continuous optimism this thesis would hardly have been completed.

I am immensely thankful to my teachers Dr. Shivani Rai Paliwal, Dr. Alpana Ram, Dr. Sunil Jain, Dr. Manoj Kumar, Dr. K. Kesavan, Dr. Akhilesh Jain, Dr. S. K. Lanjhiyana, Dr. Vivekanand Mandal, Dr. S.H Bodakhe, Dr. Nishant Jain.

And non-teaching staff especially Mr. Devi prasad Miri, Mr. Nitya Nand Singh, Mr. Murlidhar Gupta, Mr. Dhirendra sahu, Mrs. Veena Vaishnav, Mr. Virendra Kumar Verma for organizing required resources and for the assistance.

I owe a special thanks to the entire fraternity of Ph.D. Scholars for their kind help, motivation, and guidance in all stages.

A friend in need is a friend indeed. A friend gives hope when life is low. I would like to express my special thanks to my dear friends Shikha, Dimpy, Sinchan, Jagan, Priya, Vagesh, Venu anand, Nidhi, Aditya and all my M. Pharm. course mates for their well wishes and support.

I am extremely grateful to my parents for their love & prayers. Who encouraged and helped me at every stage of personal and academic life. Words fail to express my feelings of gratitude

to my beloved mother, Mrs. Chandrakala Karri and my beloved father, Mr. Kamlesh Kumar Karri. My energetic, enthusiastic and ever-loving younger brother, Nehanshu Karri, who directly and indirectly provide s pinch of spark, whenever needed, is also a highly motivating factor in the successful completion of the project. I express my parents for their support and valuable prayers.

Finally, my thanks go to all the people who have supported me to completed the research work directly or indirectly.

Tripty karri

M. Pharm final semester

#### S. No. Particulars Page No. Introduction 1. 1.1Drug Delivery system 1 1.1.1 Topical route of administration 1 1.1.2Advantages of topical route of drug administration 1 1.1.3 Thermosensitive gel 2 1.1.4mechanism thermosensitive gel 5 1.1.5Applications of forming chitosan thermosensitive hydrogel 6 **1.2Diabetic Foot Ulcer** 1.2.1 Epidemiology of DFU 6 1.2.2 Etiology of DFU 8 1.2.3 Pathophysiology of DFU 8 1.2.4 Types of DFU 11 1.2.5 Clinical Diagnosis of diabetic foot ulcer 13 1.2.6 Treatment and Management of diabetic foot ulcer 14 1.2.7 Adjuvant Therapy 15 1.3 Deferoxamine 15 1.3.1 Mechanism of action 16 1.4 Optimization of formulation (DoE) by using central composite 17 design 17 **1.5 Conclusion** 19 **1.6 References** 20 2. Literature Review 25 2.1 Work done on Thermosensitive gel 25 2.2 Work Done on Drug 27 2.3 Work Done in Diabetic Foot Ulcer 28 30 2.4 References 3. 31 Drug & Excipients profile 31 3.1 Drug profile of Deferoxamine 33 3.2 Excipient profile

# TABLE OF CONTENT

~

3.2.1 Chitosan       33         3.2.2 beta-Glycerophosphate       35         3.2.3 Streptozotocin       36         3.3 References       38         4.       Research envisaged and plan of work       40         4.1 Research envisaged and plan of work       40         4.2 Aim of work       40         4.3 plan of work       41         5.       Pre-formulation study       42         5.1 pre formulation study       42         5.1.1 List of materials used in study       42         5.1.2 List of Equipment       42         5.1.3 Method       43         5.1.4 Physicochemical and morphological characterization of       43         drug       5.1.5 Melting point       44         5.1.6 Fourier transform infrared spectral analysis       44         5.1.7 Determination of absorbance maxima (Amax)       44         5.1.7 Determination of phosphate buffer       44         5.1.8 Drug excipients compatibility       45         5.1.9 Chemical characterization of drug excipients mixture       45         5.1.1 Determination coefficient       46         5.2.2 Result and Discussion       47         5.2.1 Identification and characterization of Deferoxamine       47         5.2.3 Identification			
3.2.3 Streptozotocin363.3 References384.Research envisaged and plan of work404.1 Research envisaged404.2 Aim of work404.2 Aim of work404.3 plan of work415.Pre-formulation Study425.1 pre formulation study425.1.1 List of materials used in study425.1.2 List of Equipment425.1.3 Method435.1.4 Physicochemical and morphological characterization of43drug445.1.5 Melting point445.1.6 Fourier transform infrared spectral analysis445.1.7 Determination of absorbance maxima (Amax)445.1.7.1 Preparation of phosphate buffer455.1.8 Drug excipients compatibility455.1.9 Chemical characterization of drug excipients mixture455.1.10 Solubility study455.1.11 Partition coefficient465.2.2 melting point475.2.3 Identification and characterization of Deferoxamine475.2.1 Identification and characterization of Deferoxamine475.2.1 Identification of drug Deferoxamine by FTIR spectra485.2.4 Determination of absorption maxima of Deferoxamine505.2.4.1 Calibration cure of Deferoxamine in phosphate buffer50		3.2.1 Chitosan	33
3.3 References384.Research envisaged and plan of work404.1 Research envisaged404.2 Aim of work404.2 Aim of work404.3 plan of work415.Pre-formulation Study425.1 pre formulation study425.1.1 List of materials used in study425.1.2 List of Equipment425.1.3 Method435.1.4 Physicochemical and morphological characterization of43drug5.1.5 Melting point445.1.6 Fourier transform infrared spectral analysis445.1.7 Determination of absorbance maxima (Amax)445.1.7.1 Preparation of phosphate buffer445.1.7.2 Preparation of calibration curve for Deferoxamine455.1.8 Drug excipients compatibility455.1.10 Solubility study455.1.10 Solubility study455.1.11 Partition coefficient465.2.2 melting point475.2.3 Identification and characterization of Deferoxamine475.2.1 Identification of drug Deferoxamine by FTIR spectra485.2.4 Determination of absorption maxima of Deferoxamine475.2.4.1 Calibration curve of Deferoxamine in phosphate buffer50		3.2.2 beta-Glycerophosphate	35
4.Research envisaged and plan of work404.1 Research envisaged404.2 Aim of work404.3 plan of work415.Pre-formulation Study425.1 pre formulation study425.1.1 List of materials used in study425.1.2 List of Equipment425.1.3 Method435.1.4 Physicochemical and morphological characterization of43drug5.1.5 Melting point445.1.6 Fourier transform infrared spectral analysis445.1.7 Determination of absorbance maxima (Amax)445.1.7.1 Preparation of phosphate buffer445.1.7.2 Preparation of calibration curve for Deferoxamine455.1.8 Drug excipients compatibility455.1.9 Chemical characterization of drug excipients mixture455.1.10 Solubility study455.1.11 Partition coefficient465.2.2 melting point475.2.3 Identification and characterization of Deferoxamine475.2.3 Identification of absorption maxima of Deferoxamine475.2.4 Determination of absorption maxima of Deferoxamine475.2.4.1 Calibration curve of Deferoxamine475.2.4.2 Linearity and range50		3.2.3 Streptozotocin	36
4.1 Research envisaged404.2 Aim of work404.3 plan of work415.Pre-formulation Study425.1 pre formulation study425.1.1 List of materials used in study425.1.2 List of Equipment435.1.3 Method435.1.4 Physicochemical and morphological characterization of446 drug445.1.5 Melting point445.1.6 Fourier transform infrared spectral analysis445.1.7 Determination of absorbance maxima (Amax)445.1.7 Determination of calibration curve for Deferoxamine455.1.8 Drug excipients compatibility455.1.9 Chemical characterization of drug excipients mixture455.1.10 Solubility study455.1.10 Solubility study455.2.2 Result and Discussion475.2.3 Identification and characterization of Deferoxamine475.2.3 Identification of drug Deferoxamine by FTIR spectra485.2.4 Determination of absorption maxima of Deferoxamine495.2.4.1 Calibration cure of Deferoxamine in phosphate buffer50		3.3 References	38
4.1 Research envisaged404.2 Aim of work404.3 plan of work415.Pre-formulation Study425.1 pre formulation study425.1.1 List of materials used in study425.1.2 List of Equipment435.1.3 Method435.1.4 Physicochemical and morphological characterization of446 drug445.1.5 Melting point445.1.6 Fourier transform infrared spectral analysis445.1.7 Determination of absorbance maxima (Amax)445.1.7 Determination of calibration curve for Deferoxamine455.1.8 Drug excipients compatibility455.1.9 Chemical characterization of drug excipients mixture455.1.10 Solubility study455.1.10 Solubility study455.2.2 Result and Discussion475.2.3 Identification and characterization of Deferoxamine475.2.3 Identification of drug Deferoxamine by FTIR spectra485.2.4 Determination of absorption maxima of Deferoxamine495.2.4.1 Calibration cure of Deferoxamine in phosphate buffer50			
4.2 Aim of work404.3 plan of work415.Pre-formulation Study425.1 pre formulation study425.1.1 List of materials used in study425.1.2 List of Equipment425.1.3 Method435.1.4 Physicochemical and morphological characterization of43drug5.1.5 Melting point445.1.6 Fourier transform infrared spectral analysis445.1.7 Determination of absorbance maxima (Amax)445.1.7.1 Preparation of phosphate buffer445.1.9 Chemical characterization of drug excipients mixture455.1.9 Chemical characterization of drug excipients mixture455.1.10 Solubility study455.1.11 Partition coefficient465.2.2 melting point475.2.3 Identification of drug Deferoxamine by FTIR spectra485.2.4.2 Linearity and range51	4.	Research envisaged and plan of work	40
4.3 plan of work415.Pre-formulation Study425.1 pre formulation study425.1 pre formulation study425.1.1 List of materials used in study425.1.2 List of Equipment425.1.3 Method435.1.4 Physicochemical and morphological characterization of43drug5.1.5 Melting point445.1.5 Melting point445.1.6 Fourier transform infrared spectral analysis445.1.7 Determination of absorbance maxima (Amax)445.1.7.1 Preparation of calibration curve for Deferoxamine455.1.8 Drug excipients compatibility455.1.9 Chemical characterization of drug excipients mixture455.1.10 Solubility study455.1.11 Partition coefficient465.2 Result and Discussion475.2.1 Identification and characterization of Deferoxamine475.2.3 Identification of drug Deferoxamine by FTIR spectra485.2.4.2 Linearity and range51		4.1 Research envisaged	40
5.Pre-formulation Study425.1 pre formulation study425.1.1 List of materials used in study425.1.2 List of Equipment425.1.3 Method435.1.4 Physicochemical and morphological characterization of43drug5.1.5 Melting point445.1.6 Fourier transform infrared spectral analysis445.1.7 Determination of absorbance maxima (Amax)445.1.7.1 Preparation of phosphate buffer445.1.7.2 Preparation of calibration curve for Deferoxamine455.1.9 Chemical characterization of drug excipients mixture455.1.10 Solubility study455.1.11 Partition coefficient465.2 Result and Discussion475.2.1 Identification and characterization of Deferoxamine475.2.3 Identification of drug Deferoxamine by FTIR spectra485.2.4 Determination of absorption maxima of Deferoxamine495.2.4.1 Calibration cure of Deferoxamine in phosphate buffer50		4.2 Aim of work	40
5.1 pre formulation study425.1.1 List of materials used in study425.1.2 List of Equipment425.1.3 Method435.1.4 Physicochemical and morphological characterization of drug445.1.5 Melting point445.1.6 Fourier transform infrared spectral analysis445.1.7 Determination of absorbance maxima (Amax)445.1.7 Determination of calibration curve for Deferoxamine455.1.8 Drug excipients compatibility455.1.9 Chemical characterization of drug excipients mixture455.1.10 Solubility study455.1.11 Partition coefficient465.2 Result and Discussion475.2.1 Identification and characterization of Deferoxamine475.2.3 Identification of drug Deferoxamine by FTIR spectra485.2.4. Determination of absorption maxima of Deferoxamine505.2.4.2 Linearity and range51		4.3 plan of work	41
5.1 pre formulation study425.1.1 List of materials used in study425.1.2 List of Equipment425.1.3 Method435.1.4 Physicochemical and morphological characterization of drug445.1.5 Melting point445.1.6 Fourier transform infrared spectral analysis445.1.7 Determination of absorbance maxima (Amax)445.1.7 Determination of calibration curve for Deferoxamine455.1.8 Drug excipients compatibility455.1.9 Chemical characterization of drug excipients mixture455.1.10 Solubility study455.1.11 Partition coefficient465.2 Result and Discussion475.2.1 Identification and characterization of Deferoxamine475.2.3 Identification of drug Deferoxamine by FTIR spectra485.2.4. Determination of absorption maxima of Deferoxamine505.2.4.2 Linearity and range51			
5.1.1 List of materials used in study425.1.2 List of Equipment425.1.3 Method435.1.4 Physicochemical and morphological characterization of43drug55.1.5 Melting point445.1.6 Fourier transform infrared spectral analysis445.1.7 Determination of absorbance maxima (Amax)445.1.7.1 Preparation of phosphate buffer445.1.8 Drug excipients compatibility455.1.9 Chemical characterization of drug excipients mixture455.1.10 Solubility study455.1.11 Partition coefficient465.2 Result and Discussion475.2.3 Identification and characterization of Deferoxamine475.2.3 Identification of drug Deferoxamine by FTIR spectra485.2.4. Determination of absorption maxima of Deferoxamine505.2.4.2 Linearity and range51	5.	Pre-formulation Study	42
5.1.2 List of Equipment425.1.3 Method435.1.4 Physicochemical and morphological characterization of drug43drug15.1.5 Melting point445.1.6 Fourier transform infrared spectral analysis445.1.7 Determination of absorbance maxima (Amax)445.1.7 Determination of phosphate buffer445.1.7 Dreparation of calibration curve for Deferoxamine455.1.8 Drug excipients compatibility455.1.9 Chemical characterization of drug excipients mixture455.1.10 Solubility study455.1.11 Partition coefficient465.2 Result and Discussion475.2.1 Identification and characterization of Deferoxamine475.2.3 Identification of drug Deferoxamine by FTIR spectra485.2.4 Determination of absorption maxima of Deferoxamine495.2.4.1 Calibration cure of Deferoxamine in phosphate buffer505.2.4.2 Linearity and range51		5.1 pre formulation study	42
5.1.3 Method435.1.3 Method435.1.4 Physicochemical and morphological characterization of43drug5.1.5 Melting point445.1.5 Melting point445.1.6 Fourier transform infrared spectral analysis445.1.7 Determination of absorbance maxima (\lamax)445.1.7.1 Preparation of phosphate buffer445.1.7.2 Preparation of calibration curve for Deferoxamine455.1.8 Drug excipients compatibility455.1.9 Chemical characterization of drug excipients mixture455.1.10 Solubility study455.1.11 Partition coefficient465.2 Result and Discussion475.2.1 Identification and characterization of Deferoxamine475.2.3 Identification of drug Deferoxamine by FTIR spectra485.2.4 Determination of absorption maxima of Deferoxamine495.2.4.1 Calibration cure of Deferoxamine in phosphate buffer505.2.4.2 Linearity and range51		5.1.1 List of materials used in study	42
5.1.4 Physicochemical and morphological characterization of drug43furg5.1.5 Melting point445.1.5 Melting point445.1.6 Fourier transform infrared spectral analysis445.1.7 Determination of absorbance maxima (λmax)445.1.7.1 Preparation of phosphate buffer445.1.7.2 Preparation of calibration curve for Deferoxamine455.1.8 Drug excipients compatibility455.1.9 Chemical characterization of drug excipients mixture455.1.10 Solubility study455.1.11 Partition coefficient465.2 Result and Discussion475.2.1 Identification and characterization of Deferoxamine475.2.3 Identification of drug Deferoxamine by FTIR spectra485.2.4 Determination of absorption maxima of Deferoxamine495.2.4.1 Calibration cure of Deferoxamine in phosphate buffer505.2.4.2 Linearity and range51		5.1.2 List of Equipment	42
drug445.1.5 Melting point445.1.6 Fourier transform infrared spectral analysis445.1.6 Fourier transform infrared spectral analysis445.1.7 Determination of absorbance maxima (Amax)445.1.7 Determination of phosphate buffer445.1.7.1 Preparation of calibration curve for Deferoxamine455.1.8 Drug excipients compatibility455.1.9 Chemical characterization of drug excipients mixture455.1.10 Solubility study455.1.11 Partition coefficient465.2 Result and Discussion475.2.1 Identification and characterization of Deferoxamine475.2.2 melting point475.2.3 Identification of drug Deferoxamine by FTIR spectra485.2.4.1 Calibration cure of Deferoxamine in phosphate buffer505.2.4.2 Linearity and range51		5.1.3 Method	43
<ul> <li>5.1.5 Melting point</li> <li>5.1.6 Fourier transform infrared spectral analysis</li> <li>5.1.6 Fourier transform infrared spectral analysis</li> <li>5.1.7 Determination of absorbance maxima (\(\Lambda\)max)</li> <li>5.1.7 Determination of phosphate buffer</li> <li>5.1.7.1 Preparation of calibration curve for Deferoxamine</li> <li>5.1.8 Drug excipients compatibility</li> <li>5.1.9 Chemical characterization of drug excipients mixture</li> <li>5.1.10 Solubility study</li> <li>5.1.10 Solubility study</li> <li>5.1.11 Partition coefficient</li> <li>5.2 Result and Discussion</li> <li>5.2.1 Identification and characterization of Deferoxamine</li> <li>5.2.3 Identification of drug Deferoxamine by FTIR spectra</li> <li>5.2.4 Determination of absorption maxima of Deferoxamine</li> <li>5.2.4.1 Calibration cure of Deferoxamine in phosphate buffer</li> <li>5.2.4.2 Linearity and range</li> </ul>		5.1.4 Physicochemical and morphological characterization of	43
5.1.6 Fourier transform infrared spectral analysis445.1.6 Fourier transform infrared spectral analysis445.1.7 Determination of absorbance maxima (λmax)445.1.7 Determination of phosphate buffer445.1.7.1 Preparation of calibration curve for Deferoxamine455.1.8 Drug excipients compatibility455.1.9 Chemical characterization of drug excipients mixture455.1.10 Solubility study455.1.11 Partition coefficient465.2 Result and Discussion475.2.1 Identification and characterization of Deferoxamine475.2.3 Identification of drug Deferoxamine by FTIR spectra485.2.4 Determination of absorption maxima of Deferoxamine505.2.4.1 Calibration cure of Deferoxamine in phosphate buffer505.2.4.2 Linearity and range51		drug	
5.1.7 Determination of absorbance maxima (λmax)445.1.7 Determination of phosphate buffer445.1.7.1 Preparation of phosphate buffer445.1.7.2 Preparation of calibration curve for Deferoxamine455.1.8 Drug excipients compatibility455.1.9 Chemical characterization of drug excipients mixture455.1.10 Solubility study455.1.11 Partition coefficient465.2 Result and Discussion475.2.1 Identification and characterization of Deferoxamine475.2.2 melting point475.2.3 Identification of drug Deferoxamine by FTIR spectra485.2.4.1 Calibration cure of Deferoxamine in phosphate buffer505.2.4.2 Linearity and range51		5.1.5 Melting point	44
5.1.7.1 Preparation of phosphate buffer445.1.7.2 Preparation of calibration curve for Deferoxamine455.1.8 Drug excipients compatibility455.1.9 Chemical characterization of drug excipients mixture455.1.10 Solubility study455.1.11 Partition coefficient465.2 Result and Discussion475.2.1 Identification and characterization of Deferoxamine475.2.2 melting point475.2.3 Identification of drug Deferoxamine by FTIR spectra485.2.4.1 Calibration cure of Deferoxamine in phosphate buffer505.2.4.2 Linearity and range51		5.1.6 Fourier transform infrared spectral analysis	44
5.11/11 Treparation of phosphate outer455.1.7.2 Preparation of calibration curve for Deferoxamine455.1.8 Drug excipients compatibility455.1.9 Chemical characterization of drug excipients mixture455.1.10 Solubility study455.1.11 Partition coefficient465.2 Result and Discussion475.2.1 Identification and characterization of Deferoxamine475.2.2 melting point475.2.3 Identification of drug Deferoxamine by FTIR spectra485.2.4 Determination of absorption maxima of Deferoxamine495.2.4.1 Calibration cure of Deferoxamine in phosphate buffer505.2.4.2 Linearity and range51	1 X	5.1.7 Determination of absorbance maxima (λmax)	44
5.1.7.2 Treparation of cambration curve for Deteronamine5.1.8 Drug excipients compatibility455.1.9 Chemical characterization of drug excipients mixture455.1.10 Solubility study455.1.11 Partition coefficient465.2 Result and Discussion475.2.1 Identification and characterization of Deferoxamine475.2.2 melting point475.2.3 Identification of drug Deferoxamine by FTIR spectra485.2.4 Determination of absorption maxima of Deferoxamine495.2.4.1 Calibration cure of Deferoxamine in phosphate buffer505.2.4.2 Linearity and range51		5.1.7.1 Preparation of phosphate buffer	44
5.1.8 Ditig excipients companionly455.1.9 Chemical characterization of drug excipients mixture455.1.10 Solubility study455.1.11 Partition coefficient465.2 Result and Discussion475.2.1 Identification and characterization of Deferoxamine475.2.2 melting point475.2.3 Identification of drug Deferoxamine by FTIR spectra485.2.4 Determination of absorption maxima of Deferoxamine495.2.4.1 Calibration cure of Deferoxamine in phosphate buffer505.2.4.2 Linearity and range51		5.1.7.2 Preparation of calibration curve for Deferoxamine	45
5.1.9 Chemical characterization of drug exceptions initiate455.1.10 Solubility study455.1.11 Partition coefficient465.2 Result and Discussion475.2.1 Identification and characterization of Deferoxamine475.2.2 melting point475.2.3 Identification of drug Deferoxamine by FTIR spectra485.2.4 Determination of absorption maxima of Deferoxamine495.2.4.1 Calibration cure of Deferoxamine in phosphate buffer505.2.4.2 Linearity and range51		5.1.8 Drug excipients compatibility	45
5.1.10 Solubility study465.1.11 Partition coefficient475.2 Result and Discussion475.2.1 Identification and characterization of Deferoxamine475.2.2 melting point475.2.3 Identification of drug Deferoxamine by FTIR spectra485.2.4 Determination of absorption maxima of Deferoxamine495.2.4.1 Calibration cure of Deferoxamine in phosphate buffer505.2.4.2 Linearity and range51		5.1.9 Chemical characterization of drug excipients mixture	45
5.1.11 Farthion coefficient475.2 Result and Discussion475.2.1 Identification and characterization of Deferoxamine475.2.2 melting point475.2.3 Identification of drug Deferoxamine by FTIR spectra485.2.4 Determination of absorption maxima of Deferoxamine495.2.4.1 Calibration cure of Deferoxamine in phosphate buffer505.2.4.2 Linearity and range51		5.1.10 Solubility study	45
5.2 Result and Discussion475.2.1 Identification and characterization of Deferoxamine475.2.2 melting point475.2.3 Identification of drug Deferoxamine by FTIR spectra485.2.4 Determination of absorption maxima of Deferoxamine495.2.4.1 Calibration cure of Deferoxamine in phosphate buffer505.2.4.2 Linearity and range51		5.1.11 Partition coefficient	46
5.2.2 melting point475.2.3 Identification of drug Deferoxamine by FTIR spectra485.2.4 Determination of absorption maxima of Deferoxamine495.2.4.1 Calibration cure of Deferoxamine in phosphate buffer505.2.4.2 Linearity and range51		5.2 Result and Discussion	47
5.2.2 melting point485.2.3 Identification of drug Deferoxamine by FTIR spectra485.2.4 Determination of absorption maxima of Deferoxamine495.2.4.1 Calibration cure of Deferoxamine in phosphate buffer505.2.4.2 Linearity and range51		5.2.1 Identification and characterization of Deferoxamine	47
5.2.4 Determination of absorption maxima of Deferoxamine495.2.4.1 Calibration cure of Deferoxamine in phosphate buffer505.2.4.2 Linearity and range51		5.2.2 melting point	47
5.2.4.1 Calibration cure of Deferoxamine in phosphate buffer505.2.4.2 Linearity and range51			48
5.2.4.2 Linearity and range 51			
5.2.4.2 Linearity and range		5.2.4.1 Calibration cure of Deferoxamine in phosphate buffer	50
5.2.5 Drug and excipients compatibility study 52		5.2.4.2 Linearity and range	
		5.2.5 Drug and excipients compatibility study	52

	5.2.6 Chemical characterization of drug excipients	54
	compatibility studies	
	5.2.7 Solubility study of Deferoxamine	55
	5.2.9 Partition coefficient of Deferoxamine	56
	5.3 References	58
6	Formulation & Characterization	
	6.1 Method of formulation of thermosensitive gel	59
	6.1.1Formulation development trial	59
	6.1.1.1 preparation of optimized formulation by DoE technique	61
	6.1.2 Characterization of DFO loaded CS/β-GP prepared	61
	Thermosensitive Gel System	
	6.1.2.1 Determination of gelation temperature	61
	6.1.2.2 Determination of gelation time	61
	6.1.2.3 Determination of zeta potential	61
	6.1.2.4 pH measurement	61
	6.1.2.5 Evaluation of the thermoreversible behaviour	61
	6.1.2.6 Rheological study	62
	6.1.2.7 Scanning electron microscopy	62
	6.1.2.8 In vitro drug release study	62
	6.1.2.9 Kinetics studies of the release data	63
	6.2 Result & Discussion	64
	6.2.1 Formulation development	64
	6.2.2 Characterization of prepared Thermosensitive Gel	65
	6.2.2.1 Determination of gelation temperature	65
	6.2.2.2 Determination of gelation time	65
	6.2.2.3 Determination of zeta potential	65
	6.2.2.4 pH measurement	66
	6.2.2.5 Evaluation of the thermoreversible behaviour	66
	6.2.2.6 Rheological study	67
	6.2.2.7 Scanning electron microscopy	67
	6.2.2.8 In vitro drug release study	67
	6.2.2.9 Kinetics studies of the release data	68
	6.3 Optimization & Statistical data	69

	6.3.1-Effect on gelation temperature	70
	6.3.2-Effect on gelation time	70
	6.3.3-Effect on drug release	71
	6.3.4 Optimization of formulation	72
	6.4 Reference	73
		77
7.	Stability Studies	78
	7.1 Stability studies	78
	7.2 Stability study of optimised formulation.	78
	7.3 Result & Discussion	79
8.	In-Vivo Study	80
	8.1 Grouping of animals	80
	8.2 Induction of experimental diabetes	81
	8.3 Surgical wounding procedures	81
	8.4 Diabetic wound ulcer models	82
	8.5 Conclusion	85
	8.6 References	87
9	Histomorphology Evaluation	88
	9.1 Histomorphology Evaluation of Diabetic Plantar Soft Tissue	88
	9.2 Discussions	88
	9.3 Image analysis	89
	9.4 Conclusions	94
	9.5 References	95
10.	Summary & Conclusion	96